Global survey of guidelines for the management of epilepsy in pregnancy: A report from the international league against epilepsy task force on women and pregnancy by Tomson, Torbjörn et al.
366 |    Epilepsia Open. 2020;5:366–370.wileyonlinelibrary.com/journal/epi4
Received: 10 June 2020 | Revised: 10 July 2020 | Accepted: 15 July 2020
DOI: 10.1002/epi4.12420  
S P E C I A L  R E P O R T S
Global Survey of Guidelines for the Management of Epilepsy 
in Pregnancy: A report from the International League Against 
Epilepsy Task Force on Women and Pregnancy
Torbjörn Tomson1,2  |   Dina Battino3 |   Rebecca Bromley4,5 |   Silvia Kochen6 |    
Kimford J. Meador7  |   Page B. Pennell8 |   Sanjeev V. Thomas9
1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
2Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
3Epilepsy Center, Department of Neurophysiology and Experimental Epileptology, Fondazione IRCCS Istituto Neurologico CARLO BESTA, Milan, Italy
4Division of Evolution and Genomic Science, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health 
Science Centre, University of Manchester, Manchester, UK
5Royal Manchester Children's Hospital, Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, 
Manchester, UK
6Epilepsy Center, ENyS, CONICET, Hosp. El Cruce, Hosp. R. Mejía, Univ Buenos Aires, Buenos Aires, Argentina
7Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, CA, USA
8Divisions of Epilepsy and Women's Health, Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA
9Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Trivandrum, Kerala State, India
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Correspondence
Torbjörn Tomson, Department of Clinical 
Neuroscience, Karolinska Institutet; 
Department of Neurology, Karolinska 




NIH; NINDS, Grant/Award Number: 
#2U01-NS038455; NICHD; National 
Institute for Health Research grant, Grant/
Award Number: 2013-06-041
Abstract
The ILAE Task Force on Women and Pregnancy conducted a survey among ILAE 
Chapters of their use of guidelines or recommendations for the management of 
women with epilepsy during pregnancy. A web-based questionnaire including 10 
questions was sent to the 118 ILAE Chapters in December 2017 with repeated re-
minders until the end of February 2018. In total, 77 chapters (65%) responded, al-
though not to all questions. Out of those responding, 68% reported having guidelines 
or recommendations, 34% of which were from 2014 or earlier. At least 20% of the 
guidelines did not include information on possible risk to cognitive development, 
information regarding specific risks with specific antiepileptic drugs, nor recommen-
dations regarding selection of antiepileptic drugs. Among those responding to the 
question, 91% reported that recommendations were made regarding folate supple-
mentation, but the recommended dose ranged from 0.4 mg/d to 4 mg/d or more; 34% 
did not include recommendations regarding drug level monitoring during pregnancy, 
and 19% did not include guidelines on breastfeeding. Our survey demonstrates that 
there is a need for the development of up-to-date, globally applicable recommenda-
tions for the management of epilepsy during pregnancy.
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1 |  INTRODUCTION
The mission of the ILAE Task Force (TF) on Women and 
Pregnancy is to facilitate optimal management for women 
with epilepsy who are pregnant or of childbearing potential. 
One way to achieve this goal is by the use of evidence-based 
guidelines. There are however no official, globally approved 
or ILAE endorsed guidelines, and it is not known on what 
physicians in different countries base their management of 
pregnant women with epilepsy.
An important action of the ILAE TF on Women and 
Pregnancy was therefore to document among ILAE Chapters 
the use of guidelines or recommendations for the manage-
ment of women with epilepsy during pregnancy. The aim was 
to get an overview of the resources that already exist and are 
in use in different parts of the world, and to review to what 
extent the messages in the different guidelines are consistent 
and up to date.
2 |  METHODS
This study employed a short questionnaire which was de-
signed by members of the TF with the aim of obtaining key 
information about guideline existence and use while not 
being too long or complex to complete. An invitation to 
participate in this web-based survey was mailed to the in-
dicated contact persons of all ILAE Chapters in December 
2017 with two reminders until the end of February 2018 to 
those not responding. The survey included 10 questions on 
different aspects of recommendations for the management of 
women with epilepsy during pregnancy. The questions were 
mainly meant to investigate which issues that were covered 
by the guidelines. A few questions were designed to enquire 
about some selected specific management recommendations, 
if such were included in the guidelines, and if so what the 
recommendations were. The 10 questions are displayed in 
Table 1.
3 |  RESULTS
Out of 118 invited chapters, 77 (65%) responded to the invita-
tion to participate in the survey. Only 73 answered the ques-
tion whether they had guidelines and the chapters responded 
to a variable degree to the other 9 questions. Chapters par-
ticipating in the survey are depicted in Figure 1, demonstrat-
ing that the poorest representation was from the African 
continent. The answers to the questions are summarized in 
Table 1. Of 73 chapters responding to the first question, 50 
(68%) reported that in their country they have guidelines 
or recommendations for the management of women with 
epilepsy during pregnancy. Among those with recommenda-
tions, approximately 35% reported that these were issued by 
the national ILAE Chapter, 10% by the national neurological 
society, and 5% by national drug agencies. A substantial pro-
portion (35%) referred to guidelines issued by organizations 
from other than their own country, in particular the American 
Academy of Neurology/American Epilepsy Society1–3 or 
the UK's National Institute for Health and Care Excellence 
(NICE) guidelines.4
Figure 2 shows the year when the guidelines used by dif-
ferent chapters were issued. Some were as old as 15  years 
and a substantial proportion were issued before the year when 
the European Medicines Agency (EMA) first published their 
tightened restrictions in 2014 on the use of valproate in fe-
male patients5 and before FDA's warnings in 2013.6
Interestingly, 22% of the documents were reported not 
to include any specific recommendations on AED selec-
tions, and 26% did not include information on the possible 
risks to cognitive development posed by in utero AED ex-
posure (Table 1). Most of the responding chapters, 52 out 
of 57 (91%) reported that their guidelines included recom-
mendations regarding folate supplementation (Table  1). 
The majority favoured 4 mg/d or more, but recommended 
doses ranged from 0.4 mg/d to 4 or higher (Figure 3). Of 
the 52 that made recommendations on folate supplemen-
tation, 24 indicated that various factors had an impact 
on the dose that was recommended. Four responders re-
ported that a higher folate dose (4-5  mg/d) was recom-
mended if there was a family history or personal history 
in prior pregnancy of malformations (in particular neural 
tube defects). A few responders each mentioned that this 
K E Y W O R D S
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Key Points
• Many of the guidelines and recommendations in 
use are outdated.
• Many guidelines lack recommendations on impor-
tant aspects such as drug selection.
• Recommendations vary between countries.
• There is an urgent need for the development of up-
to-date, globally applicable recommendations.
368 |   TOMSON eT al.
high dose was preferred for women on treatment with val-
proate or carbamazepine, with “old generation” AEDs, or 
with enzyme inducing AEDs. Four chapters used low dose 
(0.4-1 mg/d) before pregnancy and high dose (3-5 mg/d) 
during pregnancy.
4 |  DISCUSSION
Among the 77 chapters responding to this survey, the ma-
jority reported having guidelines or recommendations for 
the management of women with epilepsy during pregnancy. 
The guidelines came from different sources, although most 
had been developed or endorsed by the local chapter. It is 
concerning that a significant proportion of the guidelines 
were old, and clearly published before availability of more 
recent relevant data including the latest regulatory restric-
tions on valproate use. In more than 20% of the guidelines, 
no information was provided on possible risk to cognitive 
development, which may reflect that they are of old date. 
Similar proportions of guidelines failed to indicate specific 
risks with specific AEDs, and made no recommendations 
regarding AED selection. Over the last decade, substantial 
differential risks across AED treatments have been docu-
mented, and the teratogenic risk of some AEDs extend be-




Do you have guidelines or recommendations in your 
country for the management of women with epilepsy 
during pregnancy?
73 50 (68%)
Which organization has issued the guidelines or 
recommendations that are in use in your country?
58 NA
Which year were the recommendations last updated? 56 NA
Does the document make specific recommendations on 
AED selections?
58 45 (78%)
Does it include recommendations on folate 
supplementation?
57 52 (91%)
If the recommended folate dose varies, please list the 
factors affecting the dose recommendations.
24 NA
Do your guidelines make recommendations on drug level 
monitoring during pregnancy?
58 38 (66%)
Do your guidelines provide information on specific fetal 
risks associated with specific AED treatments?
58 46 (79%)
Does the information on risks with specific AEDs include 
the possible risks to cognitive development?
58 43 (74%)
Do your guidelines include information about 
breastfeeding?
59 48 (81%)
Abbreviation: NA, not applicable.
T A B L E  1  Answers by ILAE Chapters 
to seven questions in the guideline survey
F I G U R E  1  Countries of ILAE 
Chapters that responded to the guidelines 
survey
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overly general guidelines may put patients and/or their off-
spring at risk when detailed, AED-specific information is 
now available.
More than 30% made no recommendations regarding 
drug level monitoring, and 19% did not include guidance 
regarding breastfeeding. While the vast majority addressed 
folate supplementation, the specific recommendations var-
ied considerably as to dose and timing. The latter is proba-
bly a reflection of the lack of conclusive data when it comes 
to optimal dose for folate supplementation for women 
treated with AEDs.7
While acknowledging that we do not know what the sit-
uation is in countries of chapters that did not respond to the 
survey, we see no reason to assume that availability of guide-
lines is more prevalent among non-responders compared to 
responding chapters. Our survey therefore clearly demon-
strates that there is a need for the development of up-to-date, 
globally applicable recommendations for the management of 
epilepsy during pregnancy. While there are limitations in the 
present evidence base, which leave clinicians and their pa-
tients without adequate information, the ILAE Task Force on 
Women and Pregnancy has recently published expert opinion 
recommendations in anticipation of more evidence-based 
guidelines in the future.7 Further, this TF is working with the 
ILAE Wikipedia team to create a series of pages containing 
guidance on pregnancy in women with epilepsy and their 
care which will be monitored and updated as new data and 
developments become available.
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